SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)
<i>Clostridioides</i> <i>difficile</i> infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20-25% of patients with a primary infection experience a recur...
Saved in:
Main Authors: | Sahil Khanna (Author), Matthew Sims (Author), Thomas J. Louie (Author), Monika Fischer (Author), Kerry LaPlante (Author), Jessica Allegretti (Author), Brooke R. Hasson (Author), Allyson T. Fonte (Author), Christopher McChalicher (Author), David S. Ege (Author), Jessica A. Bryant (Author), Timothy J. Straub (Author), Christopher B. Ford (Author), Matthew R. Henn (Author), Elaine E. L. Wang (Author), Lisa von Moltke (Author), Mark H. Wilcox (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
by: Kullar R, et al.
Published: (2020) -
Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
by: Matthew Sims, et al.
Published: (2023) -
Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
by: Stuart Cohen, et al.
Published: (2022) -
ANALISA PENGGUNAAN CDI RACING DAN CDI STANDAR TERHADAP UNJUK KERJA MOTOR BENSIN (110 CC)
by: Muhammad Agung Saputro, -
Published: (2015) -
Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
by: Matthew Sims, et al.
Published: (2023)